Additional information
| Active substance | Trastuzumab |
|---|---|
| Acne | No |
| Water Retention | No |
| HBR | No |
| Hepatotoxicity | No |
| Aromatization | No |
| Lab Test | HER2 testing (immunohistochemistry or fluorescence in situ hybridization) |
| Also known as | rhuMAb HER2 |
| WAREHOUSE | International Warehouse 2 |
| Blood pressure | Can cause hypertension |
| Trade name | Herceptin |
| Storage conditions | Store refrigerated at 2-8В°C (36-46В°F) |
| Chemical name | Trastuzumab |
| Formula | C6484H9996N1720O2014S44 |
| Substance class | Monoclonal antibody |
| Main action | HER2/neu receptor antagonist |
| Half-life | Approximately 28 days |
| Dosage (medical) | Typically 4 mg/kg as a loading dose followed by 2 mg/kg weekly or 6 mg/kg every three weeks |
| Dosage (sports) | Not applicable |
| Effects | Reduction in tumor growth, improved survival in breast cancer patients |
| Side effects | Fever, nausea, vomiting, infusion reactions, cardiotoxicity |
| Use in sports | None |
| Manufacturer | Roche |
Zyban Glaxosmithkline
Norvacs 5 mg Pfizer
FACTIVE 320 mg Abdi Ibragim
BIOSYNERGY RECOVERY3 PEPTIDE BLEND LIFETECH LABS
Prograf 1mg Astellas Pharma
Rovamycine 3.000.000 iu Eczacibasi
CLENBOLIC Cooper Pharma
Norvacs 10 mg Pfizer
Balkan Pharma Turanabol 10 mg 100 Tabletten
Fostimon (Merional) 75 (HMG) IBSA
Clomiphencitrat Nouveaux Ltd
Champix 56 tabs Pfizer
Avory Pharma Deca Durabolin 300mg 10ml
Zimaks 400 Bilim
Balkan Pharma Danabol 50 mg 60 Tabletten
Tavanic 500 mg Sanofi 

Reviews
There are no reviews yet.